Establishment Labs

ESTA

Market cap $1.92B

Establishment Labs Holdings Inc. (ESTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the three months and fiscal year ended December 31, 2025. Establishment Labs' preliminary unaudited revenue for the fourth quarter of 2025 is expected to be in the range of $64.0 million to $65.0 million, including $17.0 m.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. A live webcast of the presentation will be available on the Establishment Labs.

Establishment Labs files Motiva breast implants with the FDA for reconstruction, targeting expansion beyond elective augmentation into a clinically necessary market.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted Motiva® implants for approval in primary and revision breast reconstruction to the U.S. Food and Drug Administration (FDA). The products were previously approved by the FDA for use in breast augmentation on September 27, 2024. “Expanding our FD.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies 2025 London Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, November 19, 2025 at 8:30 a.m. GMT. A live webcast of the.

Establishment Labs Holdings Inc. ( ESTA ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Rajbir Denhoy - Chief Financial Officer Filippo Caldini - CEO & Director Conference Call Participants Anthony Petrone - Mizuho Americas LLC Joshua Jennings - TD Cowen, Research Division K. Gong - JPMorgan Chase & Co, Research Division Sam Eiber - BTIG, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division Presentation Operator Good afternoon.

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2025. Third Quarter Highlights and Outlook (Unaudited) Third quarter worldwide revenue of $53.8 million, an increase of 33.8% from the year ago period. Revenue included $11.9 million of Motiva sales in the.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.